Inmune Bio entered into two related agreements with certain holders of its April 2024 warrants. First, the company launched an inducement offering that reduced the exercise price to $1.40 for 50% of the warrants, resulting in the cash exercise of 647,112 warrants and approximately $905,957 in proceeds. Second, it amended the unexercised 50% of those warrants to extend their maturity from June 30, 2026 to December 31, 2027. The transactions provide immediate capital while offering holders extended optionality on remaining warrants.
Agreement 1: Inmune Bio Launches $1.40 Warrant Inducement, Raising $0.9M From 647,112 Shares
- Agreement type: Warrant inducement letter reducing exercise price and prompting partial exercise
- Counterparty: Certain holders of April 2024 Warrants
- Signed / Effective: Jun 30 2026 / same
- Duration / Termination: Until Dec 31 2027 (for remaining warrants)
- Reason: Raise cash and extend warrant runway
Agreement 2: Inmune Bio Extends Remaining April 2024 Warrants to Dec. 31, 2027
- Agreement type: Second amendment to common stock purchase warrants extending maturity
- Counterparty: Certain holders of April 2024 Warrants
- Signed / Effective: Jun 30 2026 / same
- Duration / Termination: Through Dec 31 2027
- Reason: Enhance flexibility and support longer-term capital planning
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.